16,450 Shares in Alkermes Plc (ALKS) Acquired by Tredje AP fonden

Tredje AP fonden acquired a new stake in shares of Alkermes Plc (NASDAQ:ALKS) during the first quarter, according to its most recent disclosure with the SEC. The firm acquired 16,450 shares of the company’s stock, valued at approximately $962,000.

Other hedge funds have also recently made changes to their positions in the company. Russell Investments Group Ltd. purchased a new stake in shares of Alkermes Plc during the fourth quarter valued at about $439,000. Scout Investments Inc. purchased a new stake in shares of Alkermes Plc during the third quarter valued at about $14,117,000. Baker BROS. Advisors LP purchased a new stake in shares of Alkermes Plc during the third quarter valued at about $11,769,000. Panagora Asset Management Inc. boosted its stake in shares of Alkermes Plc by 504.2% in the third quarter. Panagora Asset Management Inc. now owns 167,779 shares of the company’s stock valued at $7,891,000 after buying an additional 140,012 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. boosted its stake in shares of Alkermes Plc by 18.8% in the third quarter. D. E. Shaw & Co. Inc. now owns 1,665,836 shares of the company’s stock valued at $78,345,000 after buying an additional 264,019 shares during the last quarter. Hedge funds and other institutional investors own 95.52% of the company’s stock.

Institutional Ownership by Quarter for Alkermes Plc (NASDAQ:ALKS)

Shares of Alkermes Plc (NASDAQ:ALKS) traded up 0.94% during mid-day trading on Wednesday, hitting $58.25. The stock had a trading volume of 867,865 shares. Alkermes Plc has a one year low of $39.36 and a one year high of $62.50. The stock’s market cap is $8.92 billion. The firm has a 50 day moving average of $57.80 and a 200 day moving average of $57.07.

Alkermes Plc (NASDAQ:ALKS) last announced its quarterly earnings results on Thursday, April 27th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by $0.07. The business had revenue of $191.80 million for the quarter, compared to the consensus estimate of $195.79 million. Alkermes Plc had a negative return on equity of 12.75% and a negative net margin of 36.92%. The firm’s revenue for the quarter was up 22.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.16) EPS. On average, analysts forecast that Alkermes Plc will post ($0.04) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “16,450 Shares in Alkermes Plc (ALKS) Acquired by Tredje AP fonden” was originally posted by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://baseballnewssource.com/markets/16450-shares-in-alkermes-plc-alks-acquired-by-tredje-ap-fonden/837933.html.

Several brokerages have issued reports on ALKS. Cowen and Company restated a “positive” rating and set a $65.00 price objective on shares of Alkermes Plc in a research note on Tuesday, March 21st. Jefferies Group LLC restated a “buy” rating and set a $70.00 price objective on shares of Alkermes Plc in a research note on Monday, April 3rd. Credit Suisse Group AG set a $70.00 price objective on Alkermes Plc and gave the company a “buy” rating in a research note on Friday, May 19th. Cantor Fitzgerald restated a “neutral” rating and set a $51.00 price objective on shares of Alkermes Plc in a research note on Thursday, March 16th. Finally, JPMorgan Chase & Co. set a $78.00 price objective on Alkermes Plc and gave the company a “buy” rating in a research note on Thursday, April 27th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $63.55.

In other news, insider Shane Cooke sold 1,900 shares of Alkermes Plc stock in a transaction that occurred on Tuesday, March 21st. The shares were sold at an average price of $60.09, for a total value of $114,171.00. Following the completion of the transaction, the insider now owns 72,048 shares in the company, valued at $4,329,364.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Paul J. Mitchell sold 1,500 shares of Alkermes Plc stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $57.06, for a total transaction of $85,590.00. Following the completion of the transaction, the director now owns 9,500 shares of the company’s stock, valued at approximately $542,070. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 199,800 shares of company stock valued at $11,638,101. Corporate insiders own 4.75% of the company’s stock.

Alkermes Plc Company Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

12 Month Chart for NASDAQ:ALKS

Receive News & Ratings for Alkermes Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes Plc and related companies with our FREE daily email newsletter.

 


Latest News

David Price and Red Sox to Meet Following Rehab Start
David Price and Red Sox to Meet Following Rehab Start
Lack of Offense Leading to Mediocrity for Boston Red Sox
Lack of Offense Leading to Mediocrity for Boston Red Sox
MLB and Facebook Announce Live Streaming for Games
MLB and Facebook Announce Live Streaming for Games
Can Anyway Stop the Houston Astros?
Can Anyway Stop the Houston Astros?
Kevin Pillar Turns from Defense to Offense
Kevin Pillar Turns from Defense to Offense
Chris Iannetta Hit in Face with 93mph Fastball
Chris Iannetta Hit in Face with 93mph Fastball


Leave a Reply

 
© 2006-2017 BBNS.